Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer
Status:
Completed
Trial end date:
2019-10-08
Target enrollment:
Participant gender:
Summary
The primary goal is to prospectively estimate the median radiographic PFS of African American
and Caucasian men with mCRPC to abiraterone acetate and prednisone.